Literature DB >> 18083704

Generation and characterization of transgenic mice with the full-length human DMD gene.

Peter A C 't Hoen1, Emile J de Meijer, Judith M Boer, Rolf H A M Vossen, Rolf Turk, Ronald G H J Maatman, Kay E Davies, Gert-Jan B van Ommen, Judith C T van Deutekom, Johan T den Dunnen.   

Abstract

We report the generation of mice with an intact and functional copy of the 2.3-megabase human dystrophin gene (hDMD), the largest functional stretch of human DNA thus far integrated into a mouse chromosome. Yeast spheroplasts containing an artificial chromosome with the full-length hDMD gene were fused with mouse embryonic stem cells and were subsequently injected into mouse blastocysts to produce transgenic hDMD mice. Human-specific PCR, Southern blotting, and fluorescent in situ hybridization techniques demonstrated the intactness and stable chromosomal integration of the hDMD gene on mouse chromosome 5. Expression of the transgene was confirmed by RT-PCR and Western blotting. The tissue-specific expression pattern of the different DMD transcripts was maintained. However, the human Dp427p and Dp427m transcripts were expressed at 2-fold higher levels and human Dp427c and Dp260 transcripts were expressed at 2- and 4-fold lower levels than their endogenous counterparts. Ultimate functional proof of the hDMD transgene was obtained by crossing of hDMD mice with dystrophin-deficient mdx mice and dystrophin and utrophin-deficient mdx x Utrn-/- mice. The hDMD transgene rescued the lethal dystrophic phenotype of the mdx x Utrn-/- mice. All signs of muscular dystrophy disappeared in the rescued mice, as demonstrated by histological staining of muscle sections and gene expression profiling experiments. Currently, hDMD mice are extensively used for preclinical testing of sequence-specific therapeutics for the treatment of Duchenne muscular dystrophy. In addition, the hDMD mouse can be used to study the influence of the genomic context on deletion and recombination frequencies, genome stability, and gene expression regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083704     DOI: 10.1074/jbc.M709410200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

2.  Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.

Authors:  Jacques P Tremblay; Jean-Paul Iyombe-Engembe; Benjamin Duchêne; Dominique L Ouellet
Journal:  Mol Ther       Date:  2016-11       Impact factor: 11.454

3.  Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.

Authors:  Courtney S Young; Ekaterina Mokhonova; Marbella Quinonez; April D Pyle; Melissa J Spencer
Journal:  J Neuromuscul Dis       Date:  2017

4.  CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo.

Authors:  Benjamin L Duchêne; Khadija Cherif; Jean-Paul Iyombe-Engembe; Antoine Guyon; Joel Rousseau; Dominique L Ouellet; Xavier Barbeau; Patrick Lague; Jacques P Tremblay
Journal:  Mol Ther       Date:  2018-08-16       Impact factor: 11.454

Review 5.  Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.

Authors:  Nalinda B Wasala; Shi-Jie Chen; Dongsheng Duan
Journal:  Expert Opin Drug Discov       Date:  2020-01-30       Impact factor: 6.098

6.  Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.

Authors:  Aurélie Goyenvalle; Arran Babbs; Gert-Jan B van Ommen; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2009-05-19       Impact factor: 11.454

7.  Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast-embryonic stem cell fusion.

Authors:  Liangping Li; Thomas Blankenstein
Journal:  Nat Protoc       Date:  2013-07-18       Impact factor: 13.491

8.  A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene.

Authors:  Hidetoshi Hoshiya; Yasuhiro Kazuki; Satoshi Abe; Masato Takiguchi; Naoyo Kajitani; Yoshinori Watanabe; Toko Yoshino; Yasuaki Shirayoshi; Katsumi Higaki; Graziella Messina; Giulio Cossu; Mitsuo Oshimura
Journal:  Mol Ther       Date:  2008-11-25       Impact factor: 11.454

9.  Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.

Authors:  Maaike van Putten; Margriet Hulsker; Courtney Young; Vishna D Nadarajah; Hans Heemskerk; Louise van der Weerd; Peter A C 't Hoen; Gert-Jan B van Ommen; Annemieke M Aartsma-Rus
Journal:  FASEB J       Date:  2013-03-04       Impact factor: 5.191

Review 10.  Emerging genetic therapies to treat Duchenne muscular dystrophy.

Authors:  Stanley F Nelson; Rachelle H Crosbie; M Carrie Miceli; Melissa J Spencer
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.